CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes - Fig 1

Effects of CB1 receptor antagonist, rimonabant on body weight gain (A) and food intake (B). LETO or OLETF rats were administrated either PBS or rimonabant (10 mg/kg/day) for 6 weeks. The pair-fed OLETF rats were given the same amount of food as their counterpart rimonabant-treated OLETF rats had consumed over the previous day. Data are expressed as mean ± SEM (n = 4–5 per group). ** P < 0.01 compared to OLETF control rats (OLETF con). a P < 0.05 compared to initial body weight.